| Diabetes Mellitus
Admelog vs Tresiba
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.Deep comparison between: Admelog vs Tresiba with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTresiba has a higher rate of injection site reactions vs Admelog based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tresiba but not Admelog, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Admelog
Tresiba
At A Glance
Subcutaneous, Continuous subcutaneous infusion (pump), Intravenous
Within 15 minutes before or immediately after meals
Rapid-acting insulin analog
SC injection
Once daily
Long-acting basal insulin analog
Indications
- Diabetes Mellitus
- Diabetes Mellitus
Dosing
Diabetes Mellitus Individualize dose based on route of administration, metabolic needs, blood glucose monitoring, and glycemic control goal. Subcutaneous injection: Administer within 15 minutes before or immediately after a meal into abdominal wall, thigh, upper arm, or buttocks. Continuous subcutaneous infusion (insulin pump): Administer via pump in accordance with pump instructions; change reservoir at least every 7 days. Intravenous infusion: Administer only after dilution (0.1-1 unit/mL in 0.9% Sodium Chloride) under medical supervision. Rotate injection/infusion sites to reduce lipodystrophy risk.
Diabetes Mellitus, Type 1 SC once daily; starting dose for insulin-naive adults approximately one-third to one-half of total daily insulin dose with remainder as short-acting insulin divided among meals; when switching, adults start at same unit dose as total daily long/intermediate-acting insulin, pediatric patients (1 year and older) start at 80% of that dose.
Diabetes Mellitus, Type 2 SC once daily; starting dose 10 units for insulin-naive adults; when switching, start at same unit dose as total daily long/intermediate-acting insulin.
Contraindications
- Episodes of hypoglycemia
- Hypersensitivity to insulin lispro or any excipient in ADMELOG
- Episodes of hypoglycemia
- Hypersensitivity to insulin degludec or any excipient in TRESIBA
Adverse Reactions
Most common (>=5%) Nasopharyngitis (13%), upper respiratory tract infection (6%).
Severe hypoglycemia 13.5% in type 1 diabetes (52 weeks), 2.4% in type 2 diabetes (26 weeks).
Postmarketing Medication errors with accidental insulin substitution, localized cutaneous amyloidosis at injection site.
Most common (>=5%) Nasopharyngitis, upper respiratory tract infection, headache, sinusitis, gastroenteritis, diarrhea
Serious Hypoglycemia, hypersensitivity reactions (anaphylaxis, angioedema, bronchospasm, hypotension, shock), hypokalemia
Postmarketing Localized cutaneous amyloidosis at injection site, hyperglycemia or hypoglycemia with repeated injections into amyloidosis-affected areas
Pharmacology
Insulin lispro is a rapid-acting insulin analog that regulates glucose metabolism by stimulating peripheral glucose uptake by skeletal muscle and fat, inhibiting hepatic glucose production, inhibiting lipolysis and proteolysis, and enhancing protein synthesis.
Long-acting basal insulin analog that lowers blood glucose by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production; TRESIBA forms multi-hexamers after SC injection creating a subcutaneous depot, with protracted action due to delayed absorption from subcutaneous tissue and binding to circulating albumin.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Admelog
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Tresiba
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Admelog
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Tresiba
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Admelog
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (0/3)
Tresiba
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Admelog.
No savings programs available for Tresiba.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AdmelogView full Admelog profile
TresibaView full Tresiba profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.